Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors.

Front Nucl Med

Department of Nuclear Medicine, Red Cross Children's Hospital and Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.

Published: August 2023

Neuroendocrine tumors (NETs) are not commonly diagnosed in children. Metastatic NETs tend to have poor outcomes, and this is seen in adult and pediatric populations. The role of somatostatin receptor imaging using [Ga]Ga-DOTA-TATE for imaging and peptide receptor radionuclide therapy (PRRT) with [Lu]Lu-DOTA-TATE in children is currently not well established. The guidelines for treating pediatric neuroendocrine tumors are still lacking. Extensive trials have been conducted in adult patients and have demonstrated improved survival in metastatic NETs with PRRT using [Lu]Lu-DOTA-TATE. We present two pediatric patients with metastatic NETs who were imaged with [Ga]Ga-DOTA-TATE PET/CT and treated with [Lu]Lu-DOTA-TATE therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440991PMC
http://dx.doi.org/10.3389/fnume.2023.1193880DOI Listing

Publication Analysis

Top Keywords

neuroendocrine tumors
12
metastatic nets
12
peptide receptor
8
pediatric neuroendocrine
8
prrt [lu]lu-dota-tate
8
case report
4
report peptide
4
receptor radioligand
4
radioligand therapy
4
metastatic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!